Palisade Bio, Inc.: Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn's ...
The Manila Times

Palisade Bio Appoints Leading Global IBD Experts, Laurent Peyrin-Biroulet, MD, PhD and David T. Rubin, MD, to Its Clinical Advisory Board

Internationally recognized leaders in inflammatory bowel disease bring deep expertise spanning ulcerative colitis, Crohn’s ...

Nuance Pharma Announces Acceptance for Review of the New Drug Application for Ohtuvayre® (ensifentrine) by the National Medical Products Administration of China for the ...

Nuance Pharma ("Nuance") today announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA) for Ohtuvayre® ...
Morningstar

Korea University Researchers Revive an Abandoned Depression Drug Target Using Structurally Novel NK1 Receptor Inhibitors

Structurally novel neurokinin-1 receptor inhibitors reduce depressive-like behavior and brain inflammation in mice SEOUL, South Korea, Jan. 14, 2026 /PRNewswire/ --Researchers report that redesigning ...

Palisade Bio Announces Strategic Equity Investment from the Crohn’s & Colitis Foundation’s IBD Ventures Program to Advance PALI-2108

Detailed price information for Palisade Bio Inc (PALI-Q) from The Globe and Mail including charting and trades.
Frontiers

Refined target-mediated drug disposition modeling of the anti-tissue factor pathway inhibitor antibody MG1113 in cynomolgus monkeys and rabbits

Introduction: MG1113 is a humanized immunoglobulin G4 antibody targeting the Kunitz-type protease inhibitor 2 domain of tissue factor pathway inhibitor (TFPI) and is under clinical investigation for ...